The report covers forecast and analysis for the immuno-oncology therapy market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the immuno-oncology therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the immuno-oncology therapy market on a global level.


In order to give the users of this report a comprehensive view of the immuno-oncology therapy market, we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein therapy type segment, therapeutic area segment, and end-user segments are benchmarked based on their market size, growth rate, and general attractiveness.


The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new technology launch, agreements, partnerships, collaborations joint ventures, research development, technology and regional expansion of major participants involved in the market on the global and regional basis. Moreover, the study covers price trend analysis, the product portfolio of various companies according to the region.


The study provides a decisive view on the immuno-oncology therapy market by segmenting the market based on therapy type, therapeutic area, end-user, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. Based on therapy type the market is segmented into monoclonal antibodies, immune checkpoint inhibitors (PD1/ PDL1 and CTLA-4), immune system modulators, cancer vaccines and others. Based on the therapeutic area the market is segmented into lung cancer, colorectal cancer, breast cancer, prostate cancer, melanoma, blood cancer and other cancers. Key end-users covered under this study include hospitals, clinics, ASCs and cancer research institutes. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East Africa with its further bifurcation into major countries including the U.S., Canada, Rest of North America, U.K., Germany, France, Italy, Spain, Russia, Rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Argentina, Rest of Latin America, Saudi Arabia, UAE, Qatar, South Africa and Rest of Middle East and Africa. This segmentation includes demand for immuno-oncology therapy market based on individual therapy type, therapeutic area and end-users in all the regions and countries.


The report also includes detailed profiles of end players such as Amgen, Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Janssen Biotech, Merck and Co., Novartis AG, Pfizer, Inc., Sanofi, Spectrum Pharmaceuticals, Inc. and Takeda Pharmaceuticals.


This report segments the global immuno-oncology therapy market as follows:


Global Immuno-oncology Therapy Market: Therapy Type Segment Analysis

Monoclonal Antibodies

Immune Checkpoint Inhibitors


PD-1/ PD-L1

CTLA-4

Immune System Modulators

Cancer Vaccines

Others

Global Immuno-oncology Therapy Market: Therapeutic Area Segment Analysis

Lung Cancer

Colorectal Cancer

Breast Cancer

Prostate Cancer

Melanoma

Blood Cancer

Others Cancers

Global Immuno-oncology Therapy Market: End-user Segment Analysis

Hospitals

Clinics

Ambulatory Surgical Centers (ASCs)

Cancer Research Institutes

Global Immuno-oncology Therapy Market: Regional Segment Analysis

North America


The U.S.

Europe


UK

France

Germany

Asia Pacific


China

Japan

India

Latin America


Brazil

Middle East and Africa